Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.22 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1921
Sealed predictions
- EMC2 in dopamine neurons, braak+0.10 (p 0.802) → -0.15 (p 0.699)receipt 1928
Swarm cases
receipt 1928: EMC2 in dopamine neurons, braak
- power
- full sample -0.03 (p 0.908, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.922, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.748, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.13, sign flips 7; without severely affected donors -0.03 (p 0.908, n 18). fragile.
- cell type
- strongest in microglia: +0.62 (p 0.0062, n 18) vs -0.03 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EMC2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up EMC2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.23 p 0.424 (needs p < 7.9e-4)
Receipts
loading the receipts